高级检索
    韩宝惠. 帕博利珠单抗联合含铂化疗治疗初治的转移性非鳞状NSCLC：KEYNOTE-189的5年结果[J]. 循证医学, 2023, 23(4): 208-212. DOI: 10.12019/j.issn.1671-5144.2023.04.004
    引用本文: 韩宝惠. 帕博利珠单抗联合含铂化疗治疗初治的转移性非鳞状NSCLC：KEYNOTE-189的5年结果[J]. 循证医学, 2023, 23(4): 208-212. DOI: 10.12019/j.issn.1671-5144.2023.04.004
    shu
    HAN Bao-hui. Pemetrexed Plus Platinum With or Without Pembrolizumab in Patients With Previously Untreated Metastatic Nonsquamous NSCLC: 5-Year Outcomes From KEYNOTE-189[J]. Journal of Evidence-Based Medicine, 2023, 23(4): 208-212. DOI: 10.12019/j.issn.1671-5144.2023.04.004
    Citation: HAN Bao-hui. Pemetrexed Plus Platinum With or Without Pembrolizumab in Patients With Previously Untreated Metastatic Nonsquamous NSCLC: 5-Year Outcomes From KEYNOTE-189[J]. Journal of Evidence-Based Medicine, 2023, 23(4): 208-212. DOI: 10.12019/j.issn.1671-5144.2023.04.004
    shu

    帕博利珠单抗联合含铂化疗治疗初治的转移性非鳞状NSCLC：KEYNOTE-189的5年结果

    Pemetrexed Plus Platinum With or Without Pembrolizumab in Patients With Previously Untreated Metastatic Nonsquamous NSCLC: 5-Year Outcomes From KEYNOTE-189

      摘要
      • HTML全文
      • 参考文献(14)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回